Testosterone, blood pressure and the FDA updates: read the dates and the evidence

The February 2025 action made two different changes

In its February 28, 2025 announcement, FDA described removing boxed-warning language about increased adverse cardiovascular outcomes after reviewing TRAVERSE. It also required blood-pressure warning changes based on ambulatory blood-pressure studies. Reading only the warning-removal part leaves out a material part of the same action.

FDA said the completed blood-pressure studies confirmed increases across the testosterone product class. That is a reason for product-specific counseling and monitoring, not a statement that every person will experience the same increase. It also does not establish that every product had identical boxed wording before the change. The relevant question is what the actual medicine’s current information requires.

TRAVERSE tested a defined treatment in a defined group

The primary TRAVERSE report describes a randomized, placebo-controlled trial in men aged 45 to 80 with hypogonadism and preexisting cardiovascular disease or high cardiovascular risk. The treatment was transdermal testosterone gel, not testosterone cypionate injections. Participants had symptoms and repeated low fasting testosterone measurements under the study’s entry criteria.

Those details are part of the finding, not fine print that can be discarded. The trial can inform an important safety question while leaving other populations, formulations and routes less directly studied. It does not test an online service’s compounded preparation, its dispensing process or an individual injection plan. An advertisement citing the trial should preserve that boundary.

Noninferiority does not mean that every possible harm was absent

TRAVERSE’s main cardiovascular endpoint combined cardiovascular death, nonfatal heart attack and nonfatal stroke. The published abstract reports that testosterone gel was noninferior to placebo for that endpoint under the trial design. It also reports higher observed incidences of atrial fibrillation, acute kidney injury and pulmonary embolism in the testosterone group.

These observations should not be flattened into either complete cardiovascular danger or universal safety. The study was designed around a particular main question and had a limited follow-up period. The Endocrine Society’s July 2026 statement continues to emphasize unresolved long-term safety questions and the need for screening and monitoring. A reassuring main result does not erase other clinical considerations.

Blood pressure remains a separate follow-up responsibility

The Depo-Testosterone prescribing information checked for this guide states that testosterone can raise blood pressure and calls for periodic monitoring. It also contains cautions relevant to people with uncontrolled hypertension. This is an exact cypionate product record, not an individualized instruction or a complete safety profile for every preparation sold under the word testosterone.

Ask how blood pressure will be assessed, who receives readings and who is responsible for responding to a concerning change. Other clinicians managing cardiovascular conditions should know about the proposed treatment. This article does not supply a blood-pressure cutoff or tell you to alter either testosterone or a blood-pressure medicine. The monitoring arrangements need to come from the clinicians responsible for care.

The care team should also explain how follow-up continues when a prescription is renewed or a pharmacy changes. A new shipment does not establish that the relevant cardiovascular history, current medicines or recent measurements have been reviewed. Keep the responsibility for that review explicit.

The June 2026 request changed another part of the story

FDA’s current testosterone information page reports a June 2026 request to remove the age-related hypogonadism limitation and revise safety information concerning prostate cancer and benign prostatic hyperplasia. That supersedes treating the February 2025 decision to retain the age-related limitation as the latest FDA request.

However, the current public DailyMed Depo-Testosterone record, updated in August 2026, still displays prescribing text revised September 2025 with that limitation. The manufacturer page shows the same revision. A record-update date is not proof that every paragraph reflects every later class request. Ask the prescriber and pharmacist to reconcile the current information for the exact product, rather than assuming either that no update occurred or that every posted label has already changed.

Keep the injection’s identity separate from the class evidence

CoreAge’s page advertises testosterone cypionate at 200 mg/mL and describes the offer as compounded in the USA. That figure is a concentration, not a dose for a reader to use. The full formulation and individual dispensing pharmacy are not established by the advertisement. Its discussion of intramuscular and subcutaneous options also should not be presented as the approved route of every cypionate product.

FDA explains that compounded medicines are not FDA-approved. Neither the existence of an approved cypionate label nor the class-wide safety discussion confers approval on an unidentified compounded product. Our CoreAge review examines the public offer without making that transfer of evidence.

Use the update to ask better questions about ongoing care

A useful consultation should connect diagnosis, expected benefit, cardiovascular history and monitoring rather than use a regulatory headline to close the conversation. Our testing guide explains diagnostic confirmation, and the follow-up record guide connects test results with responsibility for reviewing them. The latest label is one part of that assessment, not a substitute for it.

Our care comparison addresses service arrangements. CoreAge appears first through this publication’s participation in its promotional publishing network, not because TRAVERSE tested that service or proved its superiority. The practical outcome should be a clear explanation of the actual medicine, relevant uncertainties and how benefit and adverse effects will be reviewed over time.